Aleksandr Mikhaylovskiy, MD
Pain Medicine · Jefferson Hills, PANPI 1134276736
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 277 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,840 and has fallen 72.2% since, to $511 in 2025.
Across 277 payments — averaging $23.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Collegium Pharmaceutical, Inc.$987
- Amgen$598
- AbbVie$592
- Abbott$521
- Boston Scientific$483
- Lilly USA, LLC$416
- plus $3K from 28 others
What the payments were for
- Food & beverage$6,467100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 65 | $987 |
| Amgen | 14 | $598 |
| AbbVie(2 entities) | 31 | $592 |
| Abbott | 8 | $521 |
| Boston Scientific | 20 | $483 |
| Lilly USA, LLC | 18 | $416 |
| Teva Pharmaceuticals USA, Inc. | 8 | $353 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 20 | $351 |
| Scilex Pharmaceuticals Inc. | 11 | $281 |
| Daiichi Sankyo Inc. | 7 | $226 |
| Si-bone, Inc. | 6 | $214 |
| Lundbeck LLC | 6 | $205 |
| Biodelivery Sciences International, Inc. | 10 | $161 |
| Virtus Pharmaceuticals LLC | 7 | $139 |
| Acorda Therapeutics, Inc | 1 | $91 |
| Vertex | 3 | $90 |
| Indivior Inc. | 6 | $87 |
| Medtronic | 4 | $86 |
| Valinor Pharma, LLC | 4 | $79 |
| Novartis | 4 | $73 |
| MDD US Operations, LLC | 5 | $63 |
| Pfizer | 3 | $60 |
| Averitas Pharma Inc. | 2 | $55 |
| GRT US Holding, Inc. | 2 | $37 |
| Almatica Pharma LLC | 2 | $33 |
| Sentynl Therapeutics, Inc. | 2 | $29 |
| Sanofi | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Redhill Biopharma Inc. | 1 | $23 |
| Shionogi Inc | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Tonix Medicines, Inc. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$463
- AIMOVIG$364
- AJOVY$208
- ZTLido 30 POUCH in 1 CARTON 1 PATCH in 1 POUCH$116
- VYEPTI$115
How this compares
$6,467 in reported general payments places this provider in the 80th percentile of 294 pain medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 44 | $26,294 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 46 | $11,869 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 580 | $8,311 |
| Buprenorphine | 46 | $7,945 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 365 | $6,626 |
| Fentanyl | 44 | $5,057 |
| Gabapentin | 228 | $4,187 |
| Morphine Sulfate ErMorphine Sulfate | 108 | $2,651 |
| Baclofen | 40 | $1,581 |
| Tramadol Hcl | 231 | $1,486 |
| Pregabalin | 36 | $1,183 |
| Celecoxib | 38 | $674 |
| Tizanidine Hcl | 35 | $485 |
| Oxycodone Hcl | 30 | $392 |
| Duloxetine Hcl | 18 | $360 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $987 | $26,29444 claims |
| Virtus Pharmaceuticals LLCLactulose | $139 | $7411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 294 pain medicine providers in Pennsylvania.
Other pain medicine in Jefferson Hills
- Peter PryzbylkowskiPhiladelphia$506K
- Yeshvant NavalgundGreensburg$388K
- Jack SmithWilliamsport$324K
- Sanjay GuptaBala Cynwyd$241K
- Vwaire OrhurhuWilliamsport$191K
- Philip KimBryn Mawr$128K
- Ajay WasanPittsburgh$66K
- Sanjay ShahSpring House$64K
- Soon JungAllentown$58K
- Bruce NicholsonAllentown$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.